Hologic, Inc. (NASDAQ:HOLX) Receives Consensus Recommendation of “Hold” from Analysts

Hologic, Inc. (NASDAQ:HOLX) has been given a consensus rating of “Hold” by the fifteen research firms that are covering the stock, Marketbeat Ratings reports. Thirteen research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $78.4167.

HOLX has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hologic in a research note on Wednesday, January 28th. Evercore cut Hologic from an “outperform” rating to an “in-line” rating and reduced their target price for the company from $79.00 to $78.00 in a report on Monday, January 5th. Mizuho lowered Hologic from an “outperform” rating to a “neutral” rating and upped their price target for the stock from $70.00 to $78.00 in a research note on Thursday, October 23rd. Needham & Company LLC reaffirmed a “hold” rating on shares of Hologic in a research note on Tuesday, November 4th. Finally, Morgan Stanley lifted their price target on shares of Hologic from $69.00 to $76.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 11th.

Hologic Trading Down 0.1%

Shares of HOLX opened at $75.14 on Friday. Hologic has a fifty-two week low of $51.90 and a fifty-two week high of $75.36. The stock has a fifty day moving average of $74.91 and a two-hundred day moving average of $71.80. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.32 and a current ratio of 4.04. The company has a market capitalization of $16.77 billion, a PE ratio of 31.31, a price-to-earnings-growth ratio of 2.24 and a beta of 0.72.

Hologic (NASDAQ:HOLX) last released its earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share for the quarter, missing the consensus estimate of $1.09 by ($0.05). The business had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.07 billion. Hologic had a return on equity of 19.58% and a net margin of 13.18%.The business’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same quarter last year, the company posted $0.87 earnings per share. As a group, analysts forecast that Hologic will post 4.28 EPS for the current year.

Institutional Trading of Hologic

Institutional investors have recently added to or reduced their stakes in the business. Winnow Wealth LLC purchased a new position in Hologic in the third quarter valued at about $26,000. Caitong International Asset Management Co. Ltd grew its stake in shares of Hologic by 193.6% in the second quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 273 shares in the last quarter. Root Financial Partners LLC purchased a new stake in shares of Hologic during the 3rd quarter valued at about $27,000. Harbor Capital Advisors Inc. acquired a new stake in Hologic during the 4th quarter valued at $27,000. Finally, SJS Investment Consulting Inc. grew its holdings in Hologic by 341.5% during the 3rd quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 362 shares in the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.